Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17036 | 1.00 | GCK (1.00) | GCKGCKR | |
| SCHEMBL30873 | 1.00 | GCK (1.00) | GCKGCKR | |
| SCHEMBL17737 | 1.00 | GCK (1.00) | GCKGCKR | |
| SCHEMBL30874 | 1.00 | GCK (1.00) | GCKGCKR | |
| SCHEMBL12079062 | 1.00 | GCK (1.00) | GCKGCKR | |
| SCHEMBL19460 | 1.00 | GCK (1.00) | GCKGCKR | |
| SCHEMBL18048 | 1.00 | GCK (1.00) | GCKGCKR | |
| SCHEMBL16871 | 0.94 | GCKR (1.00) | GCKGCKR | |
| SCHEMBL12089359 | 0.93 | GCK (0.87) | GCKGCKR | |
| SCHEMBL12089356 | 0.93 | GCK (0.87) | GCKGCKR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11690841-B2 | Glycolysis-activating agents for treatment or prevention of disease | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2023-07-04 | — | — | US | claimed |
| EP-4725482-A1 | GLUCOKINASE ACTIVATOR FOR COGNITIVE DISORDERS AND NEURODEGENERATIVE DISEASES | Hua Medicine (Shanghai) Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024251159-A1 | GLUCOKINASE ACTIVATOR FOR COGNITIVE DISORDERS AND NEURODEGENERATIVE DISEASES | 华领医药技术（上海）有限公司 | 2024-12-12 | — | — | WO | disclosed |
| CN-111491631-B | Active agent | 伦敦玛丽女王大学 | 2024-06-11 | — | — | CN | disclosed |
| US-11690841-B2 | Glycolysis-activating agents for treatment or prevention of disease | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2023-07-04 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | GCK 2/4885GCKR 1/4885 |
| US-11690841-B2 | Glycolysis-activating agents for treatment or prevention of disease | HK2, PDK1, HK1 | GCK 13/4885GCKR 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.